TY - JOUR
T1 - Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity
T2 - recommendations for clinical practice
AU - Wharton, Sean
AU - Davies, Melanie
AU - Dicker, Dror
AU - Lingvay, Ildiko
AU - Mosenzon, Ofri
AU - Rubino, Domenica M.
AU - Pedersen, Sue D.
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established in clinical practice for the treatment of type 2 diabetes, and are approved and recommended for weight management in overweight or obesity. Gastrointestinal side effects are well known as the most common adverse effects of these agents and represent a potential barrier for use, particularly at higher doses. Drawing on both published evidence and our collective clinical experience, we aim to guide practitioners through managing these side effects with a view to optimizing therapeutic outcomes with GLP-1RAs.
AB - Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established in clinical practice for the treatment of type 2 diabetes, and are approved and recommended for weight management in overweight or obesity. Gastrointestinal side effects are well known as the most common adverse effects of these agents and represent a potential barrier for use, particularly at higher doses. Drawing on both published evidence and our collective clinical experience, we aim to guide practitioners through managing these side effects with a view to optimizing therapeutic outcomes with GLP-1RAs.
UR - http://www.scopus.com/inward/record.url?scp=85120340410&partnerID=8YFLogxK
U2 - 10.1080/00325481.2021.2002616
DO - 10.1080/00325481.2021.2002616
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???
C2 - 34775881
AN - SCOPUS:85120340410
SN - 0032-5481
VL - 134
SP - 14
EP - 19
JO - Postgraduate Medicine
JF - Postgraduate Medicine
IS - 1
ER -
